Vaginosis: Advances in new therapeutic development and microbiome restoration
- PMID: 35644292
- DOI: 10.1016/j.micpath.2022.105606
Vaginosis: Advances in new therapeutic development and microbiome restoration
Abstract
Vaginosis is a condition experienced by most women at least once in their lifetime. This condition arises due to the imbalance in the microbiome of the vaginal ecosystem. Most of the pathogens of this disease are organisms which are commonly found in a normal healthy vagina. The vaginal microbiome is important as they act as a primary defence against secondary infections and Sexually transmitted diseases and infections (STDs and STIs). The vagina is mostly dominated by Lactobacillus along with other microbes including Gardnerella vaginalis, Atopobium vaginae., Prevotella spp., Mobiluncus spp., etc. Vaginal microbiome also includes Candida albicans and other species of the genus. The ratio in which these species are present varies from person to person and the dominant species decides the whether a vagina is "normal" or not. Lactobacillus dominated vagina is considered normal and if dominated by Gardnerella and such it is considered to be Bacterial vaginosis (BV) and similarly for Vulvovaginal Candidiasis (VVC). The microbiome also undergoes changes during menstrual cycles and menopausal stages. Due to the dynamic nature of this microbiome, it is tough to perfectly restore the balance. But several treatments are currently available with antibiotics like Clindamycin and derivatives of 5-nitroimidazole drugs like Metronidazole. The extensive use and the non-adherence to the treatment regimen has led to drug resistance through biofilm formation, efflux pumps, single nucleotide polymorphisms and resulting recurrent episode of vaginosis in women. Alternative medicines, preparations from plant sources, anti-microbial peptides and nano formulations are also being explored. Most of these medicines tend to focus on reducing the pathogen load rather than restoring the balance of the ecosystem. Vaginal microbiome transplant, an effort to restore the normalcy in the vaginal environment is becoming a popular treatment. In this review we discuss about the types of vaginosis, available treatments, challenges in treating the condition and the new drugs that are under investigation.
Keywords: Drug resistance; Microbiome balance; Recurrence; Restoration of microbiome; Vaginosis.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Similar articles
-
Correlation Analysis of Vaginal Microbiome Changes and Bacterial Vaginosis Plus Vulvovaginal Candidiasis Mixed Vaginitis Prognosis.Front Cell Infect Microbiol. 2022 Mar 8;12:860589. doi: 10.3389/fcimb.2022.860589. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372135 Free PMC article.
-
Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota?Microb Pathog. 2019 Sep;134:103599. doi: 10.1016/j.micpath.2019.103599. Epub 2019 Jun 15. Microb Pathog. 2019. PMID: 31212037
-
The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment.Microbiome. 2017 Aug 14;5(1):99. doi: 10.1186/s40168-017-0305-3. Microbiome. 2017. PMID: 28807017 Free PMC article. Clinical Trial.
-
Characterization of the vaginal microflora in health and disease.Dan Med J. 2014 Apr;61(4):B4830. Dan Med J. 2014. PMID: 24814599 Review.
-
Bacterial Vaginosis: What Do We Currently Know?Front Cell Infect Microbiol. 2022 Jan 18;11:672429. doi: 10.3389/fcimb.2021.672429. eCollection 2021. Front Cell Infect Microbiol. 2022. PMID: 35118003 Free PMC article. Review.
Cited by
-
Performance and Safety of a New Medical Device (Polybactum) for Reducing the Recurrence Rate of Bacterial Vaginosis: Protocol for a Multicenter, Open-Label, Noncontrolled International Clinical Trial (POLARIS Study).JMIR Res Protoc. 2023 Jul 20;12:e42787. doi: 10.2196/42787. JMIR Res Protoc. 2023. PMID: 37471117 Free PMC article.
-
Exploring the Potential Use of Probiotics, Prebiotics, Synbiotics, and Postbiotics as Adjuvants for Modulating the Vaginal Microbiome: a Bibliometric Review.Probiotics Antimicrob Proteins. 2025 Jan 17. doi: 10.1007/s12602-024-10444-8. Online ahead of print. Probiotics Antimicrob Proteins. 2025. PMID: 39821884 Review.
-
Vaginal Lactobacillus iners abundance is associated with outcome in antibiotic treatment of bacterial vaginosis and capable of inhibiting Gardnerella.Front Cell Infect Microbiol. 2022 Nov 22;12:1033431. doi: 10.3389/fcimb.2022.1033431. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36483454 Free PMC article.
-
Phytotherapy of Vulvovaginal Candidiasis: A Narrative Review.Int J Mol Sci. 2024 Mar 28;25(7):3796. doi: 10.3390/ijms25073796. Int J Mol Sci. 2024. PMID: 38612606 Free PMC article. Review.
-
Microbiota of female genital tract - functional overview of microbial flora from vagina to uterine tubes and placenta.Physiol Res. 2022 Dec 27;71(Suppl 1):S21-S33. doi: 10.33549/physiolres.934960. Physiol Res. 2022. PMID: 36592438 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous